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Abstract
Alterations in the expression of microRNAs (miRNAs) have been 
proposed to play a role in the pathogenesis of acute lymphoblastic 
leukemia (ALL) and chronic lymphocytic leukemia (CLL). 
Dicer is one of the main regulators of miRNA biogenesis, and 
deregulation of its expression has been indicated as a possible 
cause of miRNA alterations observed in various cancers. Our 
aim was to analyze the expression of the Dicer protein and its 
relationship with ALL and CLL. This cross-sectional study 
was performed from 2010 to 2012 in Shahid Faghihi Hospital, 
Shiraz, Iran. In this study, 30 patients with CLL, 21 patients 
with ALL, 10 child healthy donors, and 19 adult healthy donors 
were recruited. The patients’ samples were checked via flow 
cytometry, immunohistochemistry, and immunocytochemistry. 
The controls’ samples were also examined in the hematology 
ward. Total RNA was extracted from the bone marrow and 
peripheral blood samples of the patients and controls. Then, 
reverse-transcription polymerase chain reaction was used 
to estimate the level of Dicer miRNA. The outcomes of the 
expression analysis of Dicer revealed statistically significant 
differences between the ALL patients/child healthy controls 
(mean±SD, 0.19±0.28 vs. 0.73±0.12; P<0.001) and the CLL 
patients/adult healthy controls (mean±SD, 0.24±0.25 vs. 
0.41±0.28; P=0.033). This is the first piece of evidence showing 
that the expression of the Dicer gene greatly decreased in the 
patients with ALL in comparison to the child controls. The 
expression of the Dicer gene was also downregulated in the 
patients with CLL compared to the adult controls. Given the 
above findings, the expression of Dicer may play an important 
role in the progression and prognosis of these diseases.
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Introduction
Leukemia is a heterogeneous group of cancers caused by 
neoplastic transformation in blood cell progenitors during their 
differentiation in the bone marrow. Acute lymphoblastic leukemia 
(ALL) and chronic lymphocytic leukemia (CLL) are major 
subtypes of leukemia in most cancer registries.1 ALL progresses 
rapidly without treatment. Although it is the most common 
type of leukemia diagnosed in children, 49% of the cases are 
Brief Report
What’s Known
•	 The	 downregulation	 of	 various	
molecules and signaling pathways have 
been implicated in the pathogenesis of 
ALL and CLL; nevertheless, their exact 
pathogenesis has not been completely 
explained.
•	 The	 discovery	 of	 microRNAs	
(miRNAs) has brought a new insight 
into the pathogenesis of many diseases, 
including ALL and CLL.
What’s New
•	 We	found	that	the	expression	level	
of the Dicer gene in patients with ALL 
and	 CLL	 was	 significantly	 lower	 than	
that in child and adult normal controls, 
indicating that the abnormal expression 
of the Dicer gene may be involved in the 
development of ALL and CLL. In ALL, 
this	is	a	new	finding.
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diagnosed in patients aged 20 years and older.2 
The American Cancer Society3 estimated 
6,020 new cases and 1,440 deaths from ALL 
in the United States for 2014. Today, ALL is still 
the sixth most common malignancy in Iran.4 The 
risk factors associated with the development of 
this malignancy include environmental, genetic, 
and infectious factors. Identifying the risk factors 
for ALL is an important step in the reduction of 
the overall burden of the disease.5 CLL usually 
progresses slowly. It is the most common type 
of	leukemia	in	adults	in	Western	countries,	with	
95% of the cases occurring in those aged 50 
and older. CLL is more common in men6 with a 
male-to-female ratio of approximately 1.7:1. It 
was predicted that there would be 15,720 new 
cases of CLL in 2014, 9,100 cases in men and 
6,620 cases in women.7 By 2010, the incidence 
rate of CLL had reached 23.9% in Iran.8 There 
are very few known risk factors for CLL. Some 
studies have shown that exposure to certain 
chemical materials, family history, gender, and 
ethnicity can increase the risk of CLL.3
The downregulation of various molecules and 
signaling pathways have been implicated in the 
pathogenesis of ALL and CLL; nevertheless, their 
exact pathogenesis has not been completely 
explained. The discovery of microRNAs (miRNAs) 
has brought a new insight into the pathogenesis 
of	many	diseases,	including	ALL	and	CLL.	With	
the ability to regulate gene expression at the post-
transcriptional level and to become involved in 
important biological processes, miRNAs are small 
non-coding RNAs. There is increasing evidence 
that the various abnormal expressions of multiple 
miRNAs can play a critical role in ALL and CLL.9, 10 
However, the reasons cited for the alterations in 
the expression of miRNAs found in ALL and CLL 
have been varied. One possible theory suggests 
the defect of the miRNA biogenesis machinery 
involving Dicer and other key regulators of 
miRNA.11 Dicer is a cytoplasmic endonuclease, 
a fundamental protein component of the miRNA 
loading complex (miRLC), with a key role in 
the production of miRNAs and small interfering 
RNAs which inhibits gene expression by causing 
the destruction of specific miRNA molecules. 
This protein is encoded by DICER1 gene, which 
is located on chromosome 14 (14q32.13).12 It 
has been reported that a decreased expression 
of Dicer is associated with greater invasiveness 
and poorer survival in ovarian cancer.13 Similarly, 
low levels of Dicer and other regulators of miRLC 
have been observed in high-risk neuroblastomas 
with a poor outcome.14,15
The aim of the present study was to 
investigate altered levels of Dicer miRNA in 
patients with ALL and CLL.
Patients and Methods
This cross-sectional study was done from 
2010 to 2012 in the Molecular Pathology and 
Cytogenetic	 Ward	 of	 Shahid	 Faghihi	 Hospital,	
Shiraz, Iran. The study included 80 samples: 
30 previously untreated patients with CLL, 
21 untreated patients with ALL, 10 child controls, 
and 19 adult controls. All the patients provided 
informed consent, and the study was approved 
by the local ethics committee of the hospitals 
affiliated to Shiraz Medical University. Diagnosis 
and response were based on the criteria 
recommended by the revised criteria of the 
National Cancer Institute (NCI).16 All the patients 
were referred to our ward by oncologists. The 
diagnosis was based on peripheral smear 
and bone marrow examination subsequently 
confirmed with molecular study. Specimens with 
a total white blood cell count of 20,000 to 30,000 
were chosen, and more than 70% of them were 
leukemic cells. The patients with CLL had at 
least 5 × 109/L B lymphocytes with expressions 
of monoclonal surface immunoglobulin, CD20, 
CD5, CD19, and CD23. Patients under treatment 
were excluded from the current study. Definite 
diagnosis in all the patients was established 
based on morphology, immunocytochemistry, 
immunohistochemistry, and flow cytometry.
The normal controls’ samples were checked 
using cell counter devices (Sysmex XS-800i, 
Japan), and peripheral smears (all of them 
normal) were made from them. A description 
of the study population by gender and age is 
depicted in table 1.
Quantitative Reverse Transcription Polymerase 
Chain Reaction (Qrt-Pcr) Analysis for Dicer 
Mirna Expresion
The leukemic cells were separated by 
Ficoll-Histopaque to the bottom of Falcon 
tubes. Total RNA was extracted from the bone 
marrow and peripheral blood mononuclear cells 
using AccuZol (Bioneer, Seoul, South Korea) 
following the manufacturer’s protocol. The 
quality and quantity of RNA were assessed with 
a smart spectrophotometer (Bio-Rad, Berkeley, 
CA, U.S.A.). Retrotranscription reaction was 
performed with a High-Capacity cDNA Reverse 
Transcription	 Kit	 (Fermentas,	 Waltham,	
Massachusetts, U.S.A.) according to the 
manufacturer’s recommendations. Comparability 
between the quantitative polymerase chain 
reaction (qPCR) assays was ensured by 
obtaining standard curves through quantitative 
reverse transcription polymerase chain reaction 
(qRT-PCR) amplification of the serial dilutions 
of cDNA templates. Quantitative real-time PCR 
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was performed using a SYBR Kit (Bioneer, 
Seoul, South Korea) on an AB15700 sequence 
detection system (Applied Biosystems, Foster 
City, CA, U.S.A.) using the primers shown in 
table 2. In a total volume of 25 µL of the reaction 
mixture, 5 µL of complementary DNA templates 
was mixed with 12.5 µL of SYBR Green PCR 
Master Mix (Bioneer, Seoul, South Korea) and 
each pair of primers at a final concentration of 
200 nM. Reactions were run with the following 
thermal cycling parameters: 95 °C for 15 minutes 
followed by 50 cycles of 95 °C for 30 seconds 
(denaturation) and 60 °C for 60 seconds, melting 
curve program (60 to 95 °C) with a heating rate 
of 0.1 °C/s. The miRNA expression levels of ABL 
were used as an internal standard.
Statistical Analysis
The relative expression of Dicer in the four 
groups was calculated via the 2-∆∆ct method: 
∆ct=ct(Dicer)-ct(ABL). The efficiency of both of the 
Dicer and ABL genes was between 98 and 
102%.	 The	 Mann–Whitney	 U-test	 was	 used	
to identify statistically significant differences 
between the groups. All the statistical analyses 
were performed using the Statistical Package 
for the Social Sciences (SPSS), version 19.0 
(SPSS, Chicago, IL). The significance level was 
set	at	a	P≤0.05.
Results
All the 21 patients with ALL, 10 child controls, 
30 patients with CLL, and 19 adult controls were 
analyzed. The diagnoses were confirmed using 
conventional methods such as flow cytometry. 
No effort was spared to detect any change in 
the expression of Dicer in the patients. The age 
of the patients with ALL was between 1 and 
35 years with a median of 9.5 years, the age of 
the child controls was between 5 and 14 years 
with a median of 9.5 years, the age of the 
patients with CLL was between 40 and 84 years 
with a median of 62.9 years, and the age of the 
adult controls was between 25 and 64 years 
with a median of 51.1 years. The expression 
of the Dicer and ABL genes in the four groups 
was observed using qPCR. Taking ABL as a 
control sample, the relative expression levels 
of Dicer in the ALL patients/child controls and 
the CLL patients/adult controls were analyzed. 
There was a significant statistical difference 
between the ALL patients/child controls and the 
CLL patients/adult controls. The results of the 
real-time PCR analysis were confirmed on 2% 
agarose gel via electrophoresis and visualized 
with ethidium bromide staining (figure 1). The 
results of the expression analysis of the Dicer 
gene in the ALL patients/child controls and the 
CLL patients/adult controls are shown in table 3 
and figure 2.
Discussion
There are several dysregulations of miRNAs 
in ALL and CLL. The downregulation of miR-
15a/16-1 because of a genomic deletion in 
patients with CLL showed a relationship between 
disordered miRNA expression and developed 
hematopoietic cancer. Mice with this deletion 
expanded CLL or another leukemia type, probably 
by increasing B-cell proliferation via regulating 
cell cycle-associated genes.17 Increased B-cell 
proliferation was also considered in miR-155 
Table 1: Information on the patients and controls
Variables Cases‑ALL 
N, 21
Child controls 
N, 10
P value CLL Cases‑CLL 
N, 30
Adult controls 
N, 19
P value
Gender
Female 7 (33.33%) 4 (40%) 0.71 12 (40%) 8 (42.1%) 0.88
Male 14 (66.67%) 6 (60%) 0.56 18 (60%) 11 (57.9%) 0.11
Age
1-10 13 6 1-21 0 0
10-20 5 4 21-42 2 5
20-30 2 0 42-63 14 9
30-40 1 0 63-84 14 5
ALL: Acute lymphoblastic leukemia; CLL: Chronic lymphocytic leukemia
Table 2: Real-time primer sequences and annealing temperature
Genes Sequence (5′→3′) Product size (bp) Annealing temperature (°C)
Dicer F: CCCGGCTGAGAGAACTTACG
R: CTGTAACTTCGACCAACACCTTTAAA
103 60
ABL F: TGGAGATAACACTCTAAGCATAACTAA AGGT
R: GATGTAGTTGCTTGGGACCCA
117 60
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transgenic mice, which finally developed ALL 
and high-grade lymphoma. These studies 
demonstrate that the deregulated expression 
of miRNAs may contribute to leukemogenesis 
through disturbing the strong control of normal 
hematopoietic processes.18 The miRNA 
dysregulation may also be caused by different 
reasons. One reason that was also investigated 
in the present study is the dysregulation of the 
Dicer gene. Dicer is one of the key components 
of miRLC. The synthesis of mature endogenous 
interfering RNAs involves a cascade of events 
that are inescapably linked to the functions of 
Dicer and other components of miRLC. The 
erosion of Dicer fails the generation of most 
mature miRNAs. Koralov et al.19 showed that 
the erosion of Dicer prevented the differentiation 
of pro-B cells to pre-B cells and meaningfully 
modified antibody diversity through increasing 
the	 diversification	 of	 Igк	 variable	 regions	 and	
changing DH element usage of IgH variable 
regions. Afterward, Xu et al.20 demonstrated 
the role of Dicer in regulating B-cell terminal 
differentiation through a specific deletion of 
Dicer in murine antigen-activated B cells. 
Remarkably, after immunization with antigen, 
these mice were not capable of producing high-
affinity class-switched antibodies, memory B 
cells, and long-lived plasma cells. The results of 
a cohort study by Zhu et al.11 chime in with our 
study in so far as the downregulation of Dicer 
decreased the survival of patients with CLL; 
nonetheless, the authors extended their work 
with a karyotype study of their patients and role 
of cytogenetic change in CLL prognosis. Grelier 
et al.21 examined 104 patients with breast cancer 
and showed that the downregulation of Dicer 
decreased 5-year survival. The authors also 
demonstrated the downregulation of the Dicer 
gene in mesenchymal breast cancer. Therefore, 
Dicer is essential for functional miRNAs, which 
perform many cellular processes. Based on 
the above results, the dysregulation of Dicer in 
CLL can affect miRNAs, which play a crucial 
role in the regulation of T and B lymphocytes’ 
terminal	 differentiation.	We	also	 found	patients	
with CLL in the south of Iran, which is in line with 
other studies showing a decreased expression 
of Dicer. Nevertheless, the current literature 
contains no evidence apropos patients with ALL; 
we seem to be the first to reveal a decreased 
expression of Dicer also in patients with ALL. 
The findings of the present study showed that 
the relative expression of Dicer significantly 
decreased in the patients with CLL compared 
to the healthy controls. Our finding concerning 
the downregulation of Dicer in CLL is consistent 
with several recent reports showing that the 
expression of Dicer is significantly reduced in 
a variety of human cancers, including breast 
cancer, prostate cancer, ovarian cancer, and 
neuroblastomas.	 For	 example,	 Wu	 et	 al.15 
reported that the Dicer miRNA level was 
significantly lower in hepatocellular carcinoma 
corresponding to nonneoplastic liver tissues, 
but the expression level of this gene was 
not associated with clinical characteristics. 
Interestingly, we found a low expression of 
Dicer also in our patients with ALL, which has 
not been previously mentioned in the literature. 
In another study, it was demonstrated that the 
Table 3: Comparison of relative gene expression for the 
Dicer gene between the ALL patients/child controls and 
the CLL patients/adult controls
Gene Group N Mean±SD Range P value
Dicer ALL 21 0.19±0.28 0.00±0.93 <0.001
Child controls 10 0.73±0.12 0.56±0.94
CLL 30 0.24±0.25 0.00±0.93 0.033
Adult controls 19 0.41±0.28 0.01±0.88
*Mann–Whitney	test,	SD:	Standard	deviation
Figure 1: These pictures show the results of the real-time 
polymerase chain reaction (PCR) analysis on agarose 
gel. a) ABL gene amplification. S1: Patients with acute 
lymphoblastic leukemia (ALL); S2: Patients with chronic 
lymphocytic leukemia (CLL); L: Ladder. b) Dicer gene 
amplification. N: Control negative; S1: Patients with ALL; 
S2: Patients with CLL; L: Ladder.
Figure 2: It depicts the frequency of the expression of 
the Dicer protein in the patients with acute lymphoblastic 
leukemia (ALL) and chronic lymphocytic leukemia (CLL) 
and the child/adult controls. The expression mean of the 
Dicer protein in the patients with ALL was lower than that of 
the child controls. The expression level of this protein also 
showed a decrease in the patients with CLL compared with 
the adult controls.
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downregulation of Dicer in CLL resulted in a 
strong association with shorter overall survival 
and with reduced treatment-free survival.11 
Moreover, the findings of a study by Zighelboim 
et al.22 showed that lower DICER1 transcript 
levels were associated with disease recurrence 
and worse disease-free survival in patients with 
endometrioid endometrial carcinoma. He et al.23 
studied 90 patients with cervical cancer and 
found that the Dicer miRNA levels in 90 cervical 
cancer tissues decreased by comparison with 
normal cervix tissues. Additionally, they found 
that low expressions of the Dicer miRNA and 
protein correlated with a poor prognosis and 
relapse (including distance metastasis) of 
cervical cancer. Compared to our study, they 
found that a decreased expression of Dicer 
could be a cause of cancer.
All the above-mentioned studies are 
concordant with the current study with regard 
to miRNA levels, but they did not mention the 
expression of Dicer in ALL. However, based on 
previous studies, Dicer appears to play a tumor 
suppressor role. There is evidence for this 
notion. First, the ablation of Dicer enhanced 
tumor development in a K-ras-induced mouse 
model of lung cancer.24 Second, a low expression 
of Dicer was able to augment neuroblastoma 
tumor proliferation.14 Moreover, aggressive 
tumors are also thought to be able to decrease 
total miRNA levels and contribute to their poor 
differentiation, suggesting a decreased rather 
than an increased expression of Dicer in 
aggressive cancers.24 So far, the mechanism that 
regulates the expression of Dicer has remained 
unclear. One probable reason may be linked 
with the Dicer gene location at the subtelomeric 
region on chromosome 14 (14q32.13), which 
was detected to be affected by allelic deletion in 
several tumors, including endometrial cancer, 
lung cancer, primary neuroblastomas, chronic 
myelogenous leukemia, and lymphoma.25-28 
The other reason for the altered expression 
of Dicer is genomic mutations in this gene. 
The mutations of the Dicer gene have been 
detected in ovarian cancer and in familial 
multinodular goiter.13,29 Furthermore, epigenetic 
mechanisms may constitute another possible 
reason. Pampalakis et al.30 reported DNA 
methylation as a probable mechanism for the 
downregulation of Dicer based on the presence 
of the strong CpG island spanning the first exon 
of the gene. In light of the results of the present 
study and those reported previously, the Dicer 
gene functions as a cancer suppressor and the 
downregulation of this gene produces various 
cancers. There was no limitation to the current 
study.
Conclusion
Our findings demonstrated that the expression 
level of the Dicer gene in the patients with ALL 
and CLL was significantly lower than that in the 
child and adult normal controls, indicating that the 
abnormal expression of the Dicer gene may be 
involved in the development of ALL and CLL. The 
above results indicated that the downregulation 
of the Dicer gene is a frequent event in ALL 
and CLL and that it may be associated with 
clinicopathologic features. Our study adds new 
data to the variable expression patterns of Dicer 
in different tumor types, especially ALL.
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